DE69918072D1 - P53-regulierte gene - Google Patents

P53-regulierte gene

Info

Publication number
DE69918072D1
DE69918072D1 DE69918072T DE69918072T DE69918072D1 DE 69918072 D1 DE69918072 D1 DE 69918072D1 DE 69918072 T DE69918072 T DE 69918072T DE 69918072 T DE69918072 T DE 69918072T DE 69918072 D1 DE69918072 D1 DE 69918072D1
Authority
DE
Germany
Prior art keywords
genes
expression
regulated
bypassed
defects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69918072T
Other languages
English (en)
Other versions
DE69918072T2 (de
Inventor
J Levine
E Murphy
H Mack
C Gish
Yat Tom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affymetrix Inc
Princeton University
Original Assignee
Affymetrix Inc
Princeton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affymetrix Inc, Princeton University filed Critical Affymetrix Inc
Application granted granted Critical
Publication of DE69918072D1 publication Critical patent/DE69918072D1/de
Publication of DE69918072T2 publication Critical patent/DE69918072T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
DE69918072T 1998-03-27 1999-03-26 P53-regulierte gene Expired - Lifetime DE69918072T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49025 1998-03-27
US09/049,025 US6020135A (en) 1998-03-27 1998-03-27 P53-regulated genes
PCT/US1999/006656 WO1999050456A1 (en) 1998-03-27 1999-03-26 P53-regulated genes

Publications (2)

Publication Number Publication Date
DE69918072D1 true DE69918072D1 (de) 2004-07-22
DE69918072T2 DE69918072T2 (de) 2005-07-07

Family

ID=21957674

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69918072T Expired - Lifetime DE69918072T2 (de) 1998-03-27 1999-03-26 P53-regulierte gene

Country Status (8)

Country Link
US (3) US6020135A (de)
EP (1) EP1064404B1 (de)
JP (1) JP2002509732A (de)
AT (1) ATE269415T1 (de)
AU (1) AU3208599A (de)
CA (1) CA2324444A1 (de)
DE (1) DE69918072T2 (de)
WO (1) WO1999050456A1 (de)

Families Citing this family (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303301B1 (en) * 1997-01-13 2001-10-16 Affymetrix, Inc. Expression monitoring for gene function identification
US6355430B1 (en) * 1998-12-24 2002-03-12 Millennium Pharmaceuticals, Inc. Diagnostic and screening methods employing KIAA0101
US7179638B2 (en) 1999-07-30 2007-02-20 Large Scale Biology Corporation Microarrays and their manufacture by slicing
US6713309B1 (en) 1999-07-30 2004-03-30 Large Scale Proteomics Corporation Microarrays and their manufacture
US6936424B1 (en) * 1999-11-16 2005-08-30 Matritech, Inc. Materials and methods for detection and treatment of breast cancer
AU2001233937A1 (en) * 2000-02-22 2001-09-03 Oxford Biomedica (Uk) Limited Differential expression screening method
US6884578B2 (en) 2000-03-31 2005-04-26 Affymetrix, Inc. Genes differentially expressed in secretory versus proliferative endometrium
US6784291B2 (en) 2000-05-04 2004-08-31 Avi Biopharma, Inc. Splice-region antisense composition and method
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20040175770A1 (en) * 2000-06-30 2004-09-09 Nori Matsunami Method of screening for chemotherapeutic treatments for cancer
US7567870B1 (en) * 2000-07-31 2009-07-28 Institute For Systems Biology Multiparameter analysis for predictive medicine
DE10037769A1 (de) * 2000-08-03 2002-02-21 Epigenomics Gmbh Diagnose von mit CD24 assoziierten Krankheiten
US6713257B2 (en) * 2000-08-25 2004-03-30 Rosetta Inpharmatics Llc Gene discovery using microarrays
US7807447B1 (en) 2000-08-25 2010-10-05 Merck Sharp & Dohme Corp. Compositions and methods for exon profiling
US7108969B1 (en) * 2000-09-08 2006-09-19 Affymetrix, Inc. Methods for detecting and diagnosing oral cancer
GB0022978D0 (en) 2000-09-19 2000-11-01 Oxford Glycosciences Uk Ltd Detection of peptides
US6780594B2 (en) 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
DE10048633A1 (de) * 2000-09-25 2002-04-18 Schering Ag Methode zur in vitro Diagnostik von Endometriose
US6403372B1 (en) 2000-11-27 2002-06-11 Cytokinetics, Inc. Aspergillus fumigatus profilin
US6743897B1 (en) 2000-11-27 2004-06-01 Cytokinetics, Inc. Aspergillus fumigatus profilin
DE60237917D1 (de) * 2001-06-05 2010-11-18 Exelixis Inc Gfats als modifikatoren des p53-wegs und verwendungsverfahren
JP2004532640A (ja) * 2001-06-05 2004-10-28 オークランド ユニサーヴィスィズ リミテッド 肺機能および障害の評価のための方法および組成物
US7981842B2 (en) 2001-06-08 2011-07-19 Panomics, Inc. Method for detecting transcription factor-protein interactions
US6821737B2 (en) 2001-06-08 2004-11-23 Panomics, Inc. Method for screening for drug candidates for modulating transcription factor activity
US6696256B1 (en) * 2001-06-08 2004-02-24 Pandmics, Inc. Method, array and kit for detecting activated transcription factors by hybridization array
US20040214166A1 (en) * 2001-06-08 2004-10-28 Xianqiang Li Method for identifying a disease state based on a detected mixture of activated transcription factors
US6924113B2 (en) 2001-06-08 2005-08-02 Panomics, Inc. Method and kit for isolating DNA probes that bind to activated transcription factors
US7343247B2 (en) * 2001-07-30 2008-03-11 The Institute For Systems Biology Methods of classifying drug responsiveness using multiparameter analysis
US20030157704A1 (en) * 2001-08-29 2003-08-21 Roninson Igor B. Reagents and methods for identifying and modulating expression of genes regulated by CDK inhibitors
US7781413B2 (en) * 2001-10-31 2010-08-24 Board Of Regents, The University Of Texas System SEMA3B inhibits tumor growth and induces apoptosis in cancer cells
AU2002357368A1 (en) * 2001-12-19 2003-07-09 Affymetrix, Inc. Array plates and method for constructing array plates
US20030175713A1 (en) * 2002-02-15 2003-09-18 Clemens Sorg Method for diagnosis of inflammatory diseases using CALGRANULIN C
US20040096874A1 (en) * 2002-04-11 2004-05-20 Third Wave Technologies, Inc. Characterization of CYP 2D6 genotypes
US7504215B2 (en) 2002-07-12 2009-03-17 Affymetrix, Inc. Nucleic acid labeling methods
KR20060015446A (ko) * 2002-08-19 2006-02-17 윤 엔 간 질환의 치료 방법
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
AU2004211955B2 (en) * 2003-02-06 2009-05-14 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
WO2004074518A1 (en) * 2003-02-20 2004-09-02 Genomic Health, Inc. Use of intronic rna to measure gene expression
AU2004248140A1 (en) * 2003-05-30 2004-12-23 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
EP2327795B1 (de) 2003-06-10 2017-08-09 The Trustees Of Boston University Nachweismethoden für Lungenerkrankungen
HUE050365T2 (hu) 2003-06-24 2022-09-28 Genomic Health Inc Rákkiújulás valószínûségének elõrejelzése
AU2004258085B2 (en) * 2003-07-10 2010-05-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
EP2256201A3 (de) * 2003-09-18 2012-07-04 Isis Pharmaceuticals, Inc. Modulation der eIF4E expression
CA2542656A1 (en) * 2003-10-16 2005-05-06 Genomic Health, Inc. Qrt-pcr assay system for gene expression profiling
AU2004309396B2 (en) * 2003-12-23 2010-05-13 Genomic Health, Inc. Universal amplification of fragmented RNA
CA2497324A1 (en) 2004-02-17 2005-08-17 Affymetrix, Inc. Methods for fragmenting and labelling dna
ES2381644T3 (es) 2004-03-24 2012-05-30 Tripath Imaging, Inc. Métodos y composiciones para la detección de enfermedades de cuello uterino
ES2636470T3 (es) * 2004-04-09 2017-10-05 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
US20060073506A1 (en) 2004-09-17 2006-04-06 Affymetrix, Inc. Methods for identifying biological samples
WO2006034278A2 (en) * 2004-09-21 2006-03-30 Matritech, Inc. Methods and compositions for detecting cancer using components of the u2 spliceosomal particle
US20060073511A1 (en) 2004-10-05 2006-04-06 Affymetrix, Inc. Methods for amplifying and analyzing nucleic acids
EP1802978B1 (de) * 2004-10-14 2011-11-23 Genentech, Inc. Cop1-moleküle und verwendungen davon
US7682782B2 (en) 2004-10-29 2010-03-23 Affymetrix, Inc. System, method, and product for multiple wavelength detection using single source excitation
CA2524964A1 (en) 2004-10-29 2006-04-29 Affymetrix, Inc. Automated method of manufacturing polymer arrays
JP4939425B2 (ja) * 2004-11-05 2012-05-23 ジェノミック ヘルス， インコーポレイテッド 乳癌の治療反応の予後および予測の分子指標
CA2585571C (en) * 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
US7957507B2 (en) 2005-02-28 2011-06-07 Cadman Patrick F Method and apparatus for modulating a radiation beam
EP3211093A1 (de) 2005-04-14 2017-08-30 The Trustees of Boston University Diagnose für lungenerkrankungen mittels klassenvorhersage
US8232535B2 (en) 2005-05-10 2012-07-31 Tomotherapy Incorporated System and method of treating a patient with radiation therapy
KR20080011289A (ko) * 2005-05-10 2008-02-01 시너젠즈 바이오사이언스 리미티드 폐기능 및 폐질환을 평가하기 위한 성분 및 평가 방법
JP5421590B2 (ja) 2005-05-18 2014-02-19 ノバルティス アーゲー 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法
WO2006123955A2 (en) * 2005-05-19 2006-11-23 Synergenz Bioscience Limited Methods for the assesssment of risk of developing lung cancer using analysis of genetic polymorphisms
CA2608158A1 (en) * 2005-05-19 2006-11-23 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
WO2006123943A1 (en) * 2005-05-20 2006-11-23 Synergenz Bioscience Limited Methods of analysis of polymorphisms and uses thereof
CA2616306A1 (en) * 2005-07-22 2007-02-01 Tomotherapy Incorporated Method and system for processing data relating to a radiation therapy treatment plan
CA2616138A1 (en) * 2005-07-22 2007-02-01 Tomotherapy Incorporated System and method of monitoring the operation of a medical device
EP1907065B1 (de) * 2005-07-22 2012-11-07 TomoTherapy, Inc. Verfahren und system zur anpassung eines strahlentherapiebehandlungsplans auf der grundlage eines biologischen modells
JP2009514559A (ja) 2005-07-22 2009-04-09 トモセラピー・インコーポレーテッド 線量体積ヒストグラムを用いて輪郭構造を生成するシステムおよび方法
US8442287B2 (en) 2005-07-22 2013-05-14 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treatment plan
CN101268467B (zh) 2005-07-22 2012-07-18 断层放疗公司 用于评估治疗计划的实施中的质量保证标准的方法和系统
US7567694B2 (en) * 2005-07-22 2009-07-28 Tomotherapy Incorporated Method of placing constraints on a deformation map and system for implementing same
US7639853B2 (en) 2005-07-22 2009-12-29 Tomotherapy Incorporated Method of and system for predicting dose delivery
JP5060476B2 (ja) * 2005-07-22 2012-10-31 トモセラピー・インコーポレーテッド 放射線療法を受けている患者の呼吸位相を検出するシステムおよび方法
AU2006272742A1 (en) * 2005-07-22 2007-02-01 Tomotherapy Incorporated System and method of delivering radiation therapy to a moving region of interest
CA2616301A1 (en) * 2005-07-22 2007-02-01 Tomotherapy Incorporated Method and system for evaluating delivered dose
EP1906827A4 (de) * 2005-07-22 2009-10-21 Tomotherapy Inc System und verfahren zur evaluierung der mittels eines strahlungstherapiesystems verabreichten dosis
EP3175886B1 (de) 2005-07-23 2018-06-27 TomoTherapy, Inc. Strahlungstherapiebildgebung und abgabe mittels koordinierter bewegung von gantry und liege
ATE548467T1 (de) * 2005-09-02 2012-03-15 Univ Toledo Verfahren zur identifizierung von biomarkern mit eignung bei der diagnose biologischer zustände
WO2007044566A2 (en) * 2005-10-07 2007-04-19 Baylor Research Institute Diagnosis of systemic onset juvenile idiopathic arthritis through blood leukocyte microarray analysis
WO2007067946A2 (en) * 2005-12-07 2007-06-14 The Regents Of The University Of California Diagnosis and treatment of chronic lymphocytic leukemia (cll)
US7634363B2 (en) * 2005-12-07 2009-12-15 Affymetrix, Inc. Methods for high throughput genotyping
EP1969506A1 (de) * 2005-12-13 2008-09-17 Erasmus University Medical Center Rotterdam Genetische hirntumor-markierer
MX2008009592A (es) 2006-01-27 2008-09-08 Tripath Imaging Inc Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario.
WO2007103541A2 (en) 2006-03-09 2007-09-13 The Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
RU2008141912A (ru) 2006-03-23 2010-04-27 Новартис АГ (CH) Противоопухолевые лекарства на основе антител к клеточным антигенам
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
WO2008024114A1 (en) * 2006-08-24 2008-02-28 Genizon Biosciences Inc. Genemap of the human genes associated with schizophrenia
US20100267575A1 (en) * 2006-10-17 2010-10-21 Childrens Hospital Medical Center Gene array technique for predicting response in inflammatory bowel diseases
US9845494B2 (en) 2006-10-18 2017-12-19 Affymetrix, Inc. Enzymatic methods for genotyping on arrays
JP2010508826A (ja) 2006-11-03 2010-03-25 ベイラー リサーチ インスティテュート 血中白血球マイクロアレイ分析を介した、転移性メラノーマの診断及び免疫抑制インディケーターのモニタリング
US8293684B2 (en) * 2006-11-29 2012-10-23 Exiqon Locked nucleic acid reagents for labelling nucleic acids
US8200440B2 (en) 2007-05-18 2012-06-12 Affymetrix, Inc. System, method, and computer software product for genotype determination using probe array data
AU2009224170B2 (en) 2008-03-11 2012-03-29 National Cancer Center Method for measuring chromosome, gene or specific nucleotide sequence copy numbers using SNP array
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
ES2457534T3 (es) 2008-05-30 2014-04-28 The University Of North Carolina At Chapel Hill Perfiles de expresión génica para predecir desenlaces en cáncer de mama
AU2010226726B8 (en) 2009-03-16 2014-08-14 Pangu Biopharma Limited Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities
US20100310576A1 (en) 2009-03-31 2010-12-09 Adams Ryan A COMPOSITIONS AND METHODS COMPRISING ASPARTYL-tRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES
DK2488873T3 (en) 2009-10-16 2015-11-09 Novartis Ag Biomarkers for pharmacodynamic tumor responses
US20120282276A1 (en) 2009-11-05 2012-11-08 The Regents Of The University Of Michigan Biomarkers predictive of progression of fibrosis
US8501122B2 (en) 2009-12-08 2013-08-06 Affymetrix, Inc. Manufacturing and processing polymer arrays
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
EP2517020B1 (de) 2009-12-23 2015-10-21 Hill's Pet Nutrition, Inc. Zusammensetzungen und verfahren zur diagnostizierung und behandlung von nierenerkrankungen bei hunden
US20120296403A1 (en) 2010-02-10 2012-11-22 Novartis Ag Methods and compounds for muscle growth
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
CA2797093C (en) 2010-04-26 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
EP2563381B1 (de) 2010-04-27 2017-08-09 aTyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von isoleucyl-trna-synthetasen
CN103097524B (zh) 2010-04-28 2016-08-03 Atyr医药公司 与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
EP2563383B1 (de) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von valyl-trna-synthetasen
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
AU2011248227B2 (en) 2010-05-03 2016-12-01 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
ES2668207T3 (es) 2010-05-03 2018-05-17 Atyr Pharma, Inc. Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de metionil-ARNt sintetasas
CN103096925A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
JP6008844B2 (ja) 2010-05-04 2016-10-19 エータイアー ファーマ， インコーポレイテッド ｐ３８ＭＵＬＴＩ−ｔＲＮＡ合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
EP2568996B1 (de) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutische, diagnostische und antikörperhaltige zusammensetzungen im zusammenhang mit proteinfragmenten von phenylalanyl-beta-trna-synthetasen
US9034598B2 (en) 2010-05-17 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
CN103096913B (zh) 2010-05-27 2017-07-18 Atyr 医药公司 与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
WO2011150400A1 (en) * 2010-05-28 2011-12-01 New York Blood Center, Inc. Nuclear scaffold protein stip/tfip11 target for cancer therapy
CA2800281C (en) 2010-06-01 2021-01-12 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
CA2801107A1 (en) 2010-06-07 2011-12-15 F. Hoffman-La Roche Ag Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
ES2654994T3 (es) 2010-08-12 2018-02-15 Fate Therapeutics, Inc. Terapia mejorada con células madre y precursoras hematopoyéticas
CN103108650A (zh) 2010-08-25 2013-05-15 Atyr医药公司 与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
WO2012068170A2 (en) 2010-11-15 2012-05-24 Jau-Nan Lee Generation of neural stem cells from human trophoblast stem cells
EP2561102A1 (de) 2010-12-02 2013-02-27 Katholieke Universiteit Leuven K.U. Leuven R&D Eingriffe und diagnosen in zusammenhang mit der il-rezeptor-assoziierten kinase
AU2011360257B2 (en) 2011-02-24 2015-08-06 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing and treating kidney disorders in a feline
JP2014508165A (ja) 2011-03-02 2014-04-03 モルフォテック、インク． 乳癌の治療のためのエリブリンおよびファーレツズマブの共投与
AU2012223136B2 (en) 2011-03-02 2017-05-25 Berg Llc Interrogatory cell-based assays and uses thereof
EP2685988A4 (de) 2011-03-15 2014-08-20 Univ North Carolina Verfahren zur behandlung von brustkrebs mit einer anthracyclintherapie
EP2686441B1 (de) 2011-03-18 2019-05-08 Eisai R&D Management Co., Ltd. Verfahren und verwendungen zur vorhersage der reaktion auf eribulin
US9777332B2 (en) 2011-03-31 2017-10-03 St. Jude Children's Research Hospital Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
CN103597097B (zh) 2011-06-15 2016-08-17 希尔氏宠物营养品公司 用于诊断和监测猫科动物的甲状腺功能亢进的组合物和方法
EP2786156A2 (de) 2011-11-30 2014-10-08 AbbVie Deutschland GmbH & Co KG Verfahren und zusammensetzungen zur bestimmung des ansprechens auf eine behandlung mit einem tnf-alpha-hemmer
WO2013095935A1 (en) 2011-12-19 2013-06-27 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing and treating hyperthyroidism in companion animals
EP2814514B1 (de) 2012-02-16 2017-09-13 Atyr Pharma, Inc. Histidyl-trna-synthetasen zur behandlung von autoimmun- und entzündungserkrankungen
EP2820174B1 (de) 2012-02-27 2019-12-25 The University of North Carolina at Chapel Hill Verfahren und verwendung für molekulare tags
CA2865575C (en) 2012-02-27 2024-01-16 Cellular Research, Inc. Compositions and kits for molecular counting
MX357392B (es) 2012-04-02 2018-07-06 Berg Llc Ensayos basados en interrogatorios celulares y uso de los mismos.
EP2834371B1 (de) 2012-04-05 2019-01-09 The Regents of The University of California Genexpressionspaneel für brustkrebsprognose
CA2874492C (en) 2012-05-22 2021-10-19 British Columbia Cancer Agency Branch Nano46 genes and methods to predict breast cancer outcome
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
CN104937111B (zh) 2012-11-27 2018-05-11 智利天主教教皇大学 用于诊断甲状腺肿瘤的组合物和方法
WO2014085493A1 (en) 2012-11-30 2014-06-05 Jau-Nan Lee Methods of differentiating stem cells by modulating mir-124
AU2014207321A1 (en) 2013-01-21 2015-07-23 Abbvie Inc. Anti-TNF and anti-IL17 combination therapy biomarkers for inflammatory disease
EP2962309B1 (de) 2013-02-26 2022-02-16 Accuray, Inc. Elektromagnetisch betätigter mehrblatt-kollimator
CA2902068C (en) 2013-02-28 2023-10-03 Caprion Proteomics Inc. Tuberculosis biomarkers and uses thereof
CA2923166A1 (en) 2013-09-09 2015-03-12 British Columbia Cancer Agency Branch Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy
MX372810B (es) 2013-10-02 2020-07-03 Univ Leland Stanford Junior Composiciones de wnt y metodos para purificacion.
US10704097B2 (en) 2014-02-27 2020-07-07 Katholieke Universiteit Leuven Oxidative stress and cardiovascular disease events
WO2015127517A1 (en) 2014-02-27 2015-09-03 Katholieke Universiteit Leuven Oxidative stress and cardiovascular disease events
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
WO2015184461A1 (en) 2014-05-30 2015-12-03 Faruki Hawazin Methods for typing of lung cancer
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
CA2965217A1 (en) 2014-10-24 2016-04-28 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
BR112017007962A2 (pt) 2014-10-24 2018-01-23 Koninklijke Philips Nv método implementado por computador, aparelho, mídia de armazenamento, programa de computador, kit, e, uso do kit
ES2833543T3 (es) 2014-10-24 2021-06-15 Koninklijke Philips Nv Evaluación de la actividad de la ruta de señalización celular de TGF usando modelos matemáticos de la expresión de genes diana
US9808490B2 (en) 2014-11-26 2017-11-07 Accelerated Biosciences Corp. Induced hepatocytes and uses thereof
CN107109488A (zh) 2014-12-12 2017-08-29 麦迪韦逊前列腺治疗股份有限公司 预测对乳腺癌治疗剂的反应的方法和治疗乳腺癌的方法
ES2774457T3 (es) 2014-12-19 2020-07-21 Univ Brussel Vrije Maduración in vitro de un complejo cúmulo-ovocito de mamíferos
JP2016214239A (ja) * 2015-05-15 2016-12-22 国立大学法人高知大学 膵がんマーカー
US10066229B2 (en) 2015-07-28 2018-09-04 Otonomy, Inc. Treatment using truncated Trk B and Trk C antagonists
CA2995520A1 (en) 2015-08-14 2017-02-23 Hendrik Jan VAN OOIJEN Assessment of nfkb cellular signaling pathway activity using mathematical modelling of target gene expression
JP6858783B2 (ja) 2015-10-18 2021-04-14 アフィメトリックス インコーポレイテッド 一塩基多型及びインデルの複対立遺伝子遺伝子型決定
KR20170076480A (ko) 2015-12-24 2017-07-04 삼성전자주식회사 Pint 유전자의 발현 저해제 또는 pint의 활성 저해제를 포함하는 조성물 및 그의 용도
JP7049683B2 (ja) 2016-04-04 2022-04-07 シノピア バイオサイエンシーズ，インク． トラピジルを使用する錐体外路症候群の処置
US10934595B2 (en) 2016-05-17 2021-03-02 Genecentric Therapeutics, Inc. Methods for subtyping of lung adenocarcinoma
CA3024744A1 (en) 2016-05-17 2017-11-23 Genecentric Therapeutics, Inc. Methods for subtyping of lung squamous cell carcinoma
EP3260552A1 (de) 2016-06-20 2017-12-27 Istituto Europeo di Oncologia (IEO) Verfahren und kits mit gensignaturen zur stratifizierung von brustkrebspatienten
WO2018013883A1 (en) 2016-07-14 2018-01-18 Caprion Proteomics Inc. Biomarkers of latent tuberculosis infection
EP3487874A1 (de) 2016-07-20 2019-05-29 Westfälische Wilhelms-Universität Münster Komplexspezifische standardisierung von immunologischen verfahren zur quantifizierung von s100a12
WO2018237344A1 (en) 2017-06-22 2018-12-27 Triact Therapeutics, Inc. METHODS OF PATIENT SELECTION AND TREATMENT OF CANCERS OVEREXPRESSING TRXR OR PRDX
US11433074B2 (en) 2017-06-22 2022-09-06 Triact Therapeutics, Inc. Methods of treating glioblastoma
WO2019018764A1 (en) 2017-07-21 2019-01-24 Genecentric Therapeutics, Inc. METHODS OF DETERMINING RESPONSE TO PARP INHIBITORS
WO2019032525A1 (en) 2017-08-07 2019-02-14 Genecentric Therapeutics, Inc. PROCESS FOR SUBTYPING EPIDERMOID CARCINOMA OF HEAD AND NECK
EP3687501A4 (de) 2017-09-29 2021-06-23 Triact Therapeutics, Inc. Iniparib-formulierungen und verwendungen davon
EP3461916A1 (de) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Beurteilung der zellulären jak-stat3-signalisierungspfadaktivität mittels mathematischer modellierung der zielgenexpression
EP3461915A1 (de) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Beurteilung der aktivität von zellulären jak-stat1/2-signalisierungspfaden mittels mathematischer modellierung der zielgenexpression
EP3502279A1 (de) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Beurteilung der aktivität von zellulären mapk-ap 1-signalisierungspfaden mittels mathematischer modellierung der zielgenexpression
US12195805B2 (en) 2018-02-13 2025-01-14 Genecentric Therapeutics, Inc. Methods for subtyping of bladder cancer
ES2960914T3 (es) 2018-03-16 2024-03-07 Gopath Laboratories Llc Métodos para la detección personalizada de la reaparición del cáncer o de la metástasis y/o evaluación de la respuesta al tratamiento
WO2019232067A1 (en) 2018-05-29 2019-12-05 Centrillion Technologies, Inc. Increasing efficiency of photochemical reactions on substrates
US20210343368A1 (en) 2018-09-05 2021-11-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Method for Engineering Synthetic Cis-Regulatory DNA
CA3115922A1 (en) 2018-10-09 2020-04-16 Genecentric Therapeutics, Inc. Detecting cancer cell of origin
WO2020104482A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting metastatic potential in patients suffering from sdhb-mutated paraganglioma
US12398105B2 (en) 2018-12-20 2025-08-26 Auransa Inc. Analogues of pentamidine and uses therefor
EP3908668A4 (de) 2019-01-11 2022-11-09 University of Virginia Patent Foundation Zusammensetzungen und verfahren zur vorhersage der abnahme der lungenfunktion bei idiopathischer lungenfibrose
EP4121534A1 (de) 2020-03-18 2023-01-25 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
MX2022011879A (es) 2020-03-26 2023-01-11 Sinopia Biosciences Inc Derivados de trapidilo marcados isotopicamente.
EP3907301A1 (de) 2020-05-08 2021-11-10 Istituto Europeo di Oncologia S.r.l. Methoden und kits zur bestimmung des risikos eines erneuten auftretens von brustkrebs
EP4453261A1 (de) 2021-12-22 2024-10-30 Cornell University Prognostische/prädiktive epigenetische brustkrebssignatur

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8810400D0 (en) * 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5700637A (en) * 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
EP0390323B2 (de) * 1989-03-29 2012-08-08 Johns Hopkins University Nachweis des Ausfalls des Wildtyps des p53-Gens
US5936079A (en) * 1992-04-06 1999-08-10 Alton Ochsner Medical Foundation Oligonucleotide which binds to a chromosomal binding site for p53 protein
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
CA2118015A1 (en) * 1992-04-14 1993-10-28 Jeffrey R. Marks Method of detecting tumors containing complexes of p53 and hsp70
US5858679A (en) * 1992-11-12 1999-01-12 Fornace, Jr.; Albert J. Method for determining the presence of functional p53 by measuring GADD45 protein expression
ATE178490T1 (de) * 1993-02-16 1999-04-15 Onyx Pharmaceuticals Cytopathische viren zur therapie und prophylaxe der neoplasie
CA2177074A1 (en) * 1993-11-22 1995-06-01 James R. Bischoff P53-binding polypeptides and polynucleotides encoding same
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
US5667987A (en) * 1994-07-12 1997-09-16 Bristol-Myers Squibb Company P53 response genes
US5770377A (en) * 1994-07-20 1998-06-23 University Of Dundee Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
US5702908A (en) * 1994-07-20 1997-12-30 University Of Dundee Interruption of binding of MDM2 and p53 protein and therapeutic application thereof
US6169073B1 (en) * 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
WO1997009998A2 (en) * 1995-09-14 1997-03-20 Bristol-Myers Squibb Company Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors
DE69628936T2 (de) * 1995-09-18 2004-05-27 Cancer Research Technology Ltd. Test zur identifikation von inhibitoren der interaktion zwischen p53 und dm2 proteinen
AU8382998A (en) * 1997-07-02 1999-01-25 Genzyme Corporation P53 influenced gene expression
AU8284198A (en) * 1997-07-02 1999-01-25 Board Of Regents, The University Of Texas System P53 as a regulator of cell differentiation
DE19735221C1 (de) * 1997-08-14 1999-05-06 Wolfgang Willi Prof Dr Deppert Beeinflussung der Bindung von p53 an Zielgene
AU750187B2 (en) * 1997-09-17 2002-07-11 Johns Hopkins University, The P53-induced apoptosis
CA2305809A1 (en) * 1997-09-26 1999-04-08 University Technologies International, Inc. Use of the tumour suppressor gene p33ing1 for modulation of p53 activity and in tumour diagnosis
US6297366B1 (en) * 1998-01-14 2001-10-02 Board Of Trustees Of The University Of Illinois ING-encoded p33ING1 protein as a mediator of p53 signaling pathway in mammalian cells
DE19847779C1 (de) * 1998-10-16 2000-02-03 Deutsches Krebsforsch p53-Bindungsregionen
US6696441B1 (en) * 2000-08-11 2004-02-24 The Regents Of The University Of California Inhibition of p53-induced stress response

Also Published As

Publication number Publication date
US6171798B1 (en) 2001-01-09
EP1064404A1 (de) 2001-01-03
WO1999050456A1 (en) 1999-10-07
JP2002509732A (ja) 2002-04-02
DE69918072T2 (de) 2005-07-07
CA2324444A1 (en) 1999-10-07
AU3208599A (en) 1999-10-18
HK1038595A1 (en) 2002-03-22
EP1064404B1 (de) 2004-06-16
US20010039013A1 (en) 2001-11-08
US6020135A (en) 2000-02-01
ATE269415T1 (de) 2004-07-15

Similar Documents

Publication Publication Date Title
DE69918072D1 (de) P53-regulierte gene
Imagawa et al. Association of reduced type IX collagen gene expression in human osteoarthritic chondrocytes with epigenetic silencing by DNA hypermethylation
Esposito et al. HMGA1 pseudogenes as candidate proto-oncogenic competitive endogenous RNAs
EP0804548A4 (de) Ptc gene und ihre verwendung
EA200501772A1 (ru) Способы измерения экспрессии генов из фиксированного и залитого в парафин образца ткани
EA199800566A1 (ru) Аденовирусный вектор (варианты), способ его получения, применение, репликационно-компетентное не содержащее аденовирус потомство, способ повышения размножения в комплементирующей клеточной линии аденовирусного вектора, способ генетической модификации клетки, композиция, клетка-хозяин, способ тестирования токсичности аденовирусного вектора, способ тестирования экспрессии чужеродного гена или гена-пассажира аденовирусного вектора
DE60039072D1 (de) Verfahren zum screenen von mehrfach transformierteon von fluoreszenzproteinen
DK1115840T3 (da) Afstamningsspecifikke celler og progenitorceller
DE69822206D1 (de) Erkenntnisse der genomforschung für die suche nach neuartigen wirkstoffen
ATE257177T1 (de) Adeno-assoziierte virale (avv) liposomen und damit zusammenhängende verfahren
AU4674079A (en) Compensating the magnetic field induced by the adjacent line in series of high intensity electrolysis cells
Borok et al. Differential regulation of rat aquaporin-5 promoter/enhancer activities in lung and salivary epithelial cells
ATE171212T1 (de) Corticotropin freisetzende rezeptoren des faktor 2
WO1998005797B1 (en) Prostate cancer drug screening
EP1450602A4 (de) Identifizierung und charakterisierung von genen
DE69940022D1 (de) Promotoren für wachstums-differenzierungsfaktoren und deren verwendung
HUT73742A (en) Process for screening substances having a modulating effect on an interleukine-5-receptor-dependent cellular signal transmission path
Choder et al. RNA polymerase II allows unwinding and rewinding of the DNA and thus maintains a constant length of the transcription bubble.
DE69633131D1 (de) Rezeptor des y-y5 neuropeptids
BR9708256A (pt) Processo para identificar genes com expresão específica ao síto ou de síto preferido em células de marcacção específicas presentes em um ambiente de células diferente ou não daquele de sua origem e uso do mesmo
Karkhanina et al. Direct analysis of enzyme-catalyzed DNA demethylation
ATE297999T1 (de) Dna expression in transfizierten zellen und testverfahren in transfiziereen zellen
DE69432422D1 (de) Methoden zum aufspüren von anti-östrogenverbindungen
EP1814994A4 (de) Vorrichtung und system mit trockenen kontrollgen-verstummungszusammensetzungen
DE69715672D1 (de) Reporter-zellinie zum nachweis des cytomegalovirus und zur identifizierung von modulatoren der viralen genexpression

Legal Events

Date Code Title Description
8364 No opposition during term of opposition